APA način citiranja

Li, C., Nie, W., Guo, J., Xiong, A., Zhong, H., Chu, T., . . . Zhang, X. (2021). Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Respir Res.

Čikaški stil citiranja

Li, Changhui, et al. "Osimertinib Alone As Second-line Treatment for Brain Metastases (BM) Control May Be More Limited Than for Non-BM in Advanced NSCLC Patients With an Acquired EGFR T790M Mutation." Respir Res 2021.

MLA način citiranja

Li, Changhui, et al. "Osimertinib Alone As Second-line Treatment for Brain Metastases (BM) Control May Be More Limited Than for Non-BM in Advanced NSCLC Patients With an Acquired EGFR T790M Mutation." Respir Res 2021.